Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 0.67 |
| ▸ | CNR2 | P34972 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578707 | 0.89 | CNR2 (0.63) | FAAHCNR2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1578586 | 0.88 | CNR2 (0.85) | FAAHCNR2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15162649 | 0.87 | FAAH (0.62) | FAAHCNR2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1578558 | 0.86 | FAAH (0.67) | FAAHCNR2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL9915258 | 0.85 | GRM5 (0.56) | FAAHCNR2KMT2AMEN1AGTR1 | |
| SCHEMBL1578468 | 0.85 | GRM5 (0.56) | FAAHCNR2KMT2AMEN1AGTR1 | |
| SCHEMBL1578303 | 0.85 | FAAH (0.62) | FAAHCNR2KMT2AMEN1AGTR1 | |
| SCHEMBL1578805 | 0.85 | GRM5 (0.52) | FAAHCNR2KMT2AMEN1AGTR1 | |
| SCHEMBL9915236 | 0.85 | FAAH (0.48) | FAAHCNR2KMT2AMEN1AGTR1 | |
| SCHEMBL1578672 | 0.84 | GRM5 (0.59) | FAAHCNR2KMT2AMEN1AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947680-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S | 2011-05-24 | — | — | US | claimed |
| EP-2310356-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2011-04-20 | — | — | EP | claimed |
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| US-8389519-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-03-05 | — | — | US | disclosed |
| US-8389519-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-03-05 | — | — | US | disclosed |
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-8198275-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-8198275-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20110178086-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-07-21 | — | — | US | disclosed |
| US-20110178086-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-07-21 | — | — | US | disclosed |
| US-20110178086-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-07-21 | — | — | US | disclosed |
| US-7947680-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S | 2011-05-24 | — | — | US | disclosed |
| US-7947680-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S | 2011-05-24 | — | — | US | disclosed |
| US-7947680-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S | 2011-05-24 | — | — | US | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | FAAH 2836/4885CNR2 1628/4885KMT2A 3173/4885 |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | FAAH 2727/4885CNR2 1603/4885KMT2A 2991/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | FAAH 2906/4885CNR2 1681/4885KMT2A 3089/4885 |
| US-20110178086-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | FAAH 2836/4885CNR2 1628/4885KMT2A 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.